Zhejiang Int'l Group Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Zhejiang Int'l Group Fair Value Forecast for 2023 - 2025 - 2030
In the last year, Zhejiang Int'l Group's Price has decreased by 100.00%, going from ¥13.01 to ¥0.00. In the next year, analysts predict that Fair Value will jump to ¥0.00 – up 100.00% from the current level. Looking ahead to six years, experts forecast that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600276 Stock Forecast | Jiangsu Hengrui Medicine | Buy |
15
|
¥46.16 | Buy/Sell | ¥56.49 | 16.98% |
| T14 Stock Forecast | Tianjin Pharmaceutical Da Ren ... | Outperform |
18
|
$34.99 | Buy/Sell | $1.70 | 30.89% |
| 600436 Stock Forecast | Zhangzhou Pientzehuang Pharmac... | Outperform |
18
|
¥237.24 | Buy/Sell | ¥302.86 | 19.10% |
| 000538 Stock Forecast | Yunnan Baiyao Group Co.,Ltd | Outperform |
18
|
¥57.25 | Buy/Sell | ¥65.39 | 11.79% |
| 1093 Stock Forecast | CSPC Pharmaceutical Group | Buy |
18
|
HK$6.71 | Buy/Sell | HK$9.50 | 38.60% |
Zhejiang Int'l Group Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Zhejiang Int'l Group's Revenue has grown, moving from ¥25.01B to ¥32.05B – an increase of 28.17%. 0 analysts predict Zhejiang Int'l Group's Revenue will decrease by 7.87% in the next year, reaching ¥29.53B. By 2030, professionals predict that Zhejiang Int'l Group's Revenue will decrease by 7.95%, to ¥29.50B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000999 Stock Forecast | China Resources Sanjiu Medical... | Buy |
18
|
¥59.97 | Buy/Sell | ¥65.95 | 13.62% |
| 600085 Stock Forecast | Beijing Tongrentang | Outperform |
16
|
¥42.33 | Buy/Sell | ¥61.18 | 27.57% |
| 600196 Stock Forecast | Shanghai Fosun Pharmaceutical ... | Outperform |
16
|
¥23.67 | Buy/Sell | ¥33.57 | 20.83% |
.jpg)
Zhejiang Int'l Group Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Zhejiang Int'l Group's Dividend per Share has seen an increase, rising from ¥0.07 to ¥0.30. This represents a growth of 328.57%. For the following year, the 0 analysts predict that Zhejiang Int'l Group's Dividend per Share will drop by 28.24%, reaching ¥0.22. In 2030, the professionals' prediction is that 000411's Dividend per Share will decrease by 25.56%, reaching ¥0.22.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 002294 Stock Forecast | Shenzhen Salubris Pharmaceutic... | Buy |
18
|
¥31.92 | Buy/Sell | ¥35.65 | 15.91% |
| 600079 Stock Forecast | Humanwell Healthcare (Group) | Buy |
0
|
¥20.25 | Buy/Sell | ¥32.49 | -100.00% |
| 000513 Stock Forecast | Livzon Pharmaceutical Group | Outperform |
18
|
¥36.98 | Buy/Sell | ¥39.23 | 11.41% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600518 Stock Forecast | Kangmei Pharmaceutical | - |
6
|
¥1.99 | Buy/Sell | ¥25.97 | -100.00% |
| 300146 Stock Forecast | Byhealth | Outperform |
15
|
¥15.84 | Buy/Sell | ¥26.39 | 29.42% |
| 002262 Stock Forecast | Jiangsu Nhwa Pharmaceutical Co... | Buy |
18
|
¥25.01 | Buy/Sell | ¥31.34 | 23.95% |
Zhejiang Int'l Group EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, EBITDA for Zhejiang Int'l Group has grown by 43.45%, going from ¥641.43M to ¥920.13M. The next year, 0 experts forecast that Zhejiang Int'l Group's EBITDA will decrease by 11.31%, reaching ¥816.06M. In 2030, professionals predict that Zhejiang Int'l Group's EBITDA will decrease by 10.81%, reaching ¥820.63M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 900904 Stock Forecast | Shanghai Shenqi Pharmaceutical... | - |
13
|
$6.53 | Buy/Sell | $0.00 | -100.00% |
| 600062 Stock Forecast | China Resources Double-Crane P... | Buy |
16
|
¥21.77 | Buy/Sell | ¥26.00 | 18.24% |
| 600380 Stock Forecast | Joincare Pharmaceutical Group ... | Buy |
18
|
¥11.61 | Buy/Sell | ¥14.72 | 26.79% |
Zhejiang Int'l Group EBIT Forecast for 2023 - 2025 - 2030
Zhejiang Int'l Group's EBIT has grown in the last three years, jumping from ¥570.20M to ¥847.80M – an increase of 48.68%. According to the 0 analysts polled, in the next year, Zhejiang Int'l Group's EBIT will fall by 12.36%, reaching ¥742.98M. By 2030, professionals believe that Zhejiang Int'l Group's EBIT will have decreased by 11.88%, falling to ¥747.10M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 002773 Stock Forecast | Chengdu Kanghong Pharmaceutica... | Buy |
11
|
¥21.70 | Buy/Sell | ¥24.00 | -100.00% |
| 600867 Stock Forecast | Tonghua Dongbao Pharmaceutical | Buy |
18
|
¥10.09 | Buy/Sell | ¥14.25 | 45.49% |
| 603858 Stock Forecast | Shandong Buchang Pharmaceutica... | - |
18
|
¥16.85 | Buy/Sell | ¥0.00 | -100.00% |
Zhejiang Int'l Group EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, Zhejiang Int'l Group's EPS has decreased by 100.00%, going from ¥0.25 to ¥0.00. In the next year, analysts predict that EPS will jump to ¥0.00 – up 100.00% from the current level. Looking ahead to six years, experts forecast that EPS will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000623 Stock Forecast | Jilin Aodong Pharmaceutical Gr... | Buy |
16
|
¥15.28 | Buy/Sell | ¥0.00 | 48.36% |
| 600422 Stock Forecast | KPC Pharmaceuticals,Inc | Buy |
18
|
¥22.72 | Buy/Sell | ¥28.00 | 10.08% |
| 000766 Stock Forecast | Tonghua Golden-Horse Pharmaceu... | - |
11
|
¥17.16 | Buy/Sell | ¥33.00 | -100.00% |
.jpg)